Skip to content
Advertisement

FILE - In this Aug. 6, 2020, file photo provided by Russian Direct Investment Fund, an employee works with a coronavirus vaccine at the Nikolai Gamaleya National Center of Epidemiology and Microbiology in Moscow, Russia. Russia’s boast in August that it was the first country to authorize a coronavirus vaccine led to skepticism because of its insufficient testing on only a few dozen people. Now, with demand growing for the Sputnik V, experts are raising questions again, this time over whether Moscow can keep up with all the orders from countries that want it. (Alexander Zemlianichenko Jr/Russian Direct Investment Fund via AP, File)

FILE - In this Aug. 6, 2020, file photo provided by Russian Direct Investment Fund, an employee works with a coronavirus vaccine at the Nikolai Gamaleya National Center of Epidemiology and Microbiology in Moscow, Russia. Russia’s boast in August that it was the first country to authorize a coronavirus vaccine led to skepticism because of its insufficient testing on only a few dozen people. Now, with demand growing for the Sputnik V, experts are raising questions again, this time over whether Moscow can keep up with all the orders from countries that want it. (Alexander Zemlianichenko Jr/Russian Direct Investment Fund via AP, File)

Featured Photo Galleries